|
Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus Clinical research trials and Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus. Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus clinical trial. Test subjects typically receive the most expert healthcare available for their Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus  Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus
Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus
For Condition: Gastric Cancer,Esophageal Neoplasms
Status: Suspended
Sponsor(s): Tularik ,
Synopsis: This is a clinical research study of T900607-sodium to determine if it is effective and safe in treating gastric cancer and adenocarcinoma of the esophagus. Patients will be treated on a weekly basis with an intravenous injection of the study drug.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - Histologically or cytologically confirmed diagnosis of gastric cancer or adenocarcinoma of the esophagus - Subjects must have received 1-2 regimens of prior chemotherapy - At least 18 years of age - Bidimensionally measurable disease amenable to CT scanning. At least one lesion must be least 1 X 1 cm in size. - Karnofsky performance status of at least 70% - Estimated life expectancy of at least 12 weeks - Females of childbearing potential must have a negative pregnancy test and agree to use an effective contraceptive - Subject must be able to comply with study procedures and follow-up examinations. - Signed written informed consent - Lab Values (obtained 7 days prior to study enrollment): * ANC at least 1.5x10e9/L, * Platelet count at least 100x10e9/L, * Creatinine within 2 times upper limit of normal * AST and ALT within 5 times upper limit of normal * Bilirubin within 1.5 times upper limit of normal * Albumin great than 2.5 g/dL Exclusion Criteria - Severe, concurrent disease, infection or co-morbidity that, in the judgment of the investigator, would make the subject inappropriate for enrollment - NYHA Class III/IV cardiac disease, left ventricular ejection fraction (LVEF) of <50%, or acute anginal symptoms - Patients who have received any investigational agent within 4 weeks of enrollment - Patients who are pregnant or breast-feeding - History of prior malignancy other than gastric cancer or adenocarcinoma of the esophagus within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix - History of central nervous system metastases or carcinomatous meningitis - Major surgery within 4 weeks of enrollment
Total Enrollment: 70
Location and Contact Information:
Overall Study Official:
KerrieBoyd, Study Chair,
Pacific Oncology Associates
Los Gatos, California, 95032
United States
Moffitt Cancer Center
Tampa, Florida, 33612
United States
Scripps Health Center
San Diego, California, 92137
United States
Ireland Cancer Center
Cleveland, Ohio, 44106
United States
University of New Mexico Cancer Research and Treatment Center
Albuquerque, New Mexico, 87131
United States
Additional Information:
Study ID Numbers: T-607-006;
Study Start Date: September 2002
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00048529
Other Gastric Cancer Studies:
1. Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction
2. Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer
3. Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
4. Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction
5. Oblimersen, Cisplatin, and Fluorouracil in Treating Patients With Advanced Esophageal, Gastroesophageal Junction, or Stomach Cancer
Related Studies:
Other Gastric Cancer Clinical Trials
Other California Clinical Trials
Other San Diego Clinical Trials
Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus
|
|
|
|
|
|
|
|
